You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of a topical fixed-dose combination drug for peripheral neuropathic pain.
SBC: WinSanTor, Inc. Topic: NINDSPROJECT SUMMARY An estimated 30 million people in the United States suffer from some form of peripheral neuropathy, a condition that develops as a result of damage to the peripheral nervous system. The top two major causes of peripheral neuropathy in the US are diabetes mellitus (both T1DM and T2DM) and chemotherapeutic agents. Currently, there are no FDA-approved treatments to prevent or reverse ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Inhibitors of T3SS translocon assembly to combat multi-drug resistant P. aeruginosa
SBC: MICROBIOTIX, INC. Topic: NIAIDAbstract Pseudomonas aeruginosa (PA) is the bacterium most frequently isolated from the respiratory tract of ICU pa- tients in the US and is a major cause of pneumonia in intubated patients. Furthermore, infection with PA gener- ally has a poor prognosis, with an estimated 40-69% of PA ventilator-associated pneumonia (VAP) cases re- sulting in mortality, and more than 30% of survivors suffer recur ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Salmonella typhimurium-based Bacteriotherapy for Orphan Benign Tumors: Neurofibromatosis Type II (NF2)
SBC: Mulberry Biotherapeutics, Inc. Topic: 102Neurofibromatosis type 2 (NF2) is a rare genetic disorder that affects about 1 in 25,000 individuals globally. While usually benign, these tumors result in severe morbidity and mortality in affected individuals. Almost all NF2 patients lose their hearing, and many lose the ability to walk and even to see. NF2 patients’ average age at death is 36 years, many of whom die in adolescence or early ad ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease
SBC: Planet Biotechnology Incorporated Topic: NIAIDLyme disease (LD) is the most prevalent vector-borne disease in the United States, with up to 300,000 cases a year. LD is caused by several species of the spirochete bacteria Borrelia burgdorferi sensu lato (the Lyme borreliae), which are transmitted by ticks from animal (bird, rodent) reservoirs to human hosts. While a short course of antibiotics is usually effective in eliminating the bacteria a ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Development of a Caregiver Application and AI-Enabled Intelligent Assistant to Support Families and Formal Care Providers in Caring for Persons with Alzheimer's Disease and Related Dementias
SBC: Whiplash Technology, Inc. Topic: NIAPROJECT ABSTRACT Family caregivers face daunting challenges in caring for persons with Alzheimer’s disease. Currently, there is no widely available mechanism to provide real-time, context sensitive support to informal AD caregivers that can address the specific care needs of each AD patient. To address this critical gap, we developed CareVirtue, an innovative web/mobile application for family ca ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Engineering a unique antibody for patients with RA
SBC: ABWIZ BIO INC Topic: NIAIDRA is one of the most common chronic autoimmune disorders that can lead to complete joint destruction and severe disability if untreated. There is no cure for RA and up to 50% of RA patients do not respond to anti-TNF therapies as circulating Th-17/IL-17 levels are highly elevated subsequent to TNF blockade. For this subset of RA patients, disruption of a novel pathway that impairs the synergy bet ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A Portable PET Insert System for Simultaneous TOF-PET and MR Brain Imaging
SBC: PETcoil, Inc. Topic: 101Project Summary Medical imaging technologies such as magnetic resonance imaging (MRI) and positron emission tomography (PET) have been widely used in studying the underlying mechanisms of mental illnesses and neurological disorders such as brain tumors, Alzheimer’s disease, epilepsy, and depression, etc. However, PET and MRI scans are almost always ordered as separate studies on separate machine ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Delivery of chemically modified PNA oligomers
SBC: NUBAD LLC Topic: NIAIDPROJECT SUMMARYRNA is a validated target for drug design, both as therapeutic and as a target. Targeting specific RNA, such as rRNA which are involved in proliferation and survival of bacteria is a promising approach. We are developing fast and low cost methods to screen sequence-specific small molecules for novel anti-ribosomal activities. We will construct sequence-specific chemically modified r ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
HBI-002 to Prevent Anthracycline-Related Cardiotoxicity
SBC: Hillhurst Biopharmaceuticals, Inc. Topic: NHLBIPROJECT SUMMARY There is an urgent need for the development of approaches to prevent cardiotoxicity in cancer patients being treated with anthracyclines, an important class of drugs in the treatment of cancer (e.g. doxorubicin). Anthracycline treatment-related cardiotoxicity is a major clinical problem that severely impacts patient care and also limits dose and usage. More than a quarter of patien ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Reversal of Tau Pathology with MSUT2 siRNA Conjugates
SBC: DTx Pharma, Inc. Topic: NIAProject Summary Genetic and pathologic evidence in andapos;pureandapos; tauopathies such as Progressive Supranuclear Palsy (PSP), Corticobasilar Degeneration (CBD) and some cases of Fronto-temporal Dementia (FTD) directly implicate tau as causing neuronal cell death, while in Alzheimer’s Disease (AD) tau accumulation correlates with development and progression of cognitive impairment. Because of ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health